Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Abstract Text:

Jolien M Bueno-de-Mesquita,Wim H van Harten,Valesca P Retel,Laura J van 't Veer,Frits Sam van Dam,Kim Karsenberg,Kirsten Fl Douma,Harm van Tinteren,Johannes L Peterse,Jelle Wesseling,Tin S Wu,Douwe Atsma,Emiel Jt Rutgers,Guido Brink,Arno N Floore,Annuska M Glas,Rudi Mh Roumen,Frank E Bellot,Cees van Krimpen,Sjoerd Rodenhuis,Marc J van de Vijver,Sabine C Linn,Jolien M Bueno-de-Mesquita,Wim H van Harten,Valesca P Retel,Laura J van't Veer,Frits S A M van Dam,Kim Karsenberg,Kirsten F L Douma,Harm van Tinteren,Johannes L Peterse,Jelle Wesseling,Tin S Wu,Douwe Atsma,Emiel J T Rutgers,Guido Brink,Arno N Floore,Annuska M Glas,Rudi M H Roumen,Frank E Bellot,Cees van Krimpen,Sjoerd Rodenhuis,Marc J van de Vijver,Sabine C Linn,Jolien M Bueno-de-Mesquita,Wim H van Harten,Valesca P Retel,Laura J van't Veer,Frits S A M van Dam,Kim Karsenberg,Kirsten F L Douma,Harm van Tinteren,Johannes L Peterse,Jelle Wesseling,Tin S Wu,Douwe Atsma,Emiel J T Rutgers,Guido Brink,Arno N Floore,Annuska M Glas,Rudi M H Roumen,Frank E Bellot,Cees van Krimpen,Sjoerd Rodenhuis,Marc J van de Vijver,Sabine C Linn,Jolien M Bueno-de-Mesquita,Wim H van Harten,Valesca P Retel,Laura J van't Veer,Frits S A M van Dam,Kim Karsenberg,Kirsten F L Douma,Harm van Tinteren,Johannes L Peterse,Jelle Wesseling,Tin S Wu,Douwe Atsma,Emiel J T Rutgers,Guido Brink,Arno N Floore,Annuska M Glas,Rudi M H Roumen,Frank E Bellot,Cees van Krimpen,Sjoerd Rodenhuis,Marc J van de Vijver,Sabine C Linn,

BACKGROUND: A microarray-based 70-gene prognosis signature might improve the selection of patients with node-negative breast cancer for adjuvant systemic treatment. The main aims of this MicroarRAy PrognoSTics in Breast CancER (RASTER) study were to assess prospectively the feasibility of implementation of the 70-gene prognosis signature in community-based settings and its effect on adjuvant systemic treatment decisions when considered with treatment advice formulated from the Dutch Institute for Healthcare Improvement (CBO) and other guidelines. METHODS: Between January, 2004 and December, 2006, 812 women aged under 61 years with primary breast carcinoma (clinical T1-4N0M0) were enrolled. Fresh tumour samples were collected in 16 hospitals in the Netherlands within 1 h after surgery. Clinicopathological factors were collected and microarray analysis was done with a custom-designed array chip that assessed the mRNA expression index of the 70 genes previously identified for the prognostic signature. Patients with a "good" signature were deemed to have a good prognosis and, therefore, could be spared adjuvant systemic treatment with its associated adverse effects, whereas patients with a "poor" signature were judged to have a poor prognosis and should be considered for adjuvant systemic treatment. Concordance between risk predicted by the prognosis signature and risk predicted by commonly used clinicopathological guidelines (ie, St Gallen guidelines, Nottingham Prognostic Index, and Adjuvant! Online) was assessed. FINDINGS: Of 585 eligible patients, 158 patients were excluded because of sampling failure (n=128) and incorrect procedure (n=30). Prognosis signatures were assessed in 427 patients. The 70-gene prognosis signature identified 219 (51%) patients with good prognosis and 208 (49%) patients with poor prognosis. The Dutch CBO guidelines identified 184 patients (43%) with poor prognosis, which was discordant with those findings obtained with the prognosis signature in 128 (30%) patients. Oncologists recommended adjuvant treatment in 203 (48%) patients based on Dutch CBO guidelines, in 265 (62%) patients if the guidelines were used with the prognosis signature, and in 259 (61%) patients if Dutch CBO guidelines, prognosis signature, and patients' preferences for treatment were all taken into account. Adjuvant! Online guidelines identified more patients with poor prognosis than did the signature alone (294 [69%]), and discordance with the signature occurred in 160 (37%) patients. St Gallen guidelines identified 353 (83%) patients with poor prognosis with the signature and discordance in 168 (39%) patients. Nottingham Prognostic Index recorded 179 (42%) patients with poor prognosis with the signature and discordance in 117 (27%) patients. INTERPRETATION: Use of the prognosis signature is feasible in Dutch community hospitals. Adjuvant systemic treatment was advised less often when the more restrictive Dutch CBO guidelines were used compared with that finally given after use of the prognosis signature. For the other guidelines assessed, less adjuvant chemotherapy would be given when the data based on prognosis signature alone are used, which might spare patients from adverse effects and confirms previous findings. Future studies should assess whether use of the prognosis signature could improve survival or equal survival while avoiding unnecessary adjuvant systemic treatment without affecting patients' survival, and further assess the factors that physicians use to recommend adjuvant systemic treatment.

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Publishing Authors By Initials

JM Bueno-de-Mesquita,WH van Harten,VP Retel,LJ van 't Veer,FS van Dam,K Karsenberg,KF Douma,H van Tinteren,JL Peterse,J Wesseling,TS Wu,D Atsma,EJ Rutgers,G Brink,AN Floore,AM Glas,RM Roumen,FE Bellot,C van Krimpen,S Rodenhuis,MJ van de Vijver,SC Linn,JM Bueno-de-Mesquita,WH van Harten,VP Retel,LJ van't Veer,FS van Dam,K Karsenberg,KF Douma,H van Tinteren,JL Peterse,J Wesseling,TS Wu,D Atsma,EJ Rutgers,G Brink,AN Floore,AM Glas,RM Roumen,FE Bellot,C van Krimpen,S Rodenhuis,MJ van de Vijver,SC Linn,JM Bueno-de-Mesquita,WH van Harten,VP Retel,LJ van't Veer,FS van Dam,K Karsenberg,KF Douma,H van Tinteren,JL Peterse,J Wesseling,TS Wu,D Atsma,EJ Rutgers,G Brink,AN Floore,AM Glas,RM Roumen,FE Bellot,C van Krimpen,S Rodenhuis,MJ van de Vijver,SC Linn,JM Bueno-de-Mesquita,WH van Harten,VP Retel,LJ van't Veer,FS van Dam,K Karsenberg,KF Douma,H van Tinteren,JL Peterse,J Wesseling,TS Wu,D Atsma,EJ Rutgers,G Brink,AN Floore,AM Glas,RM Roumen,FE Bellot,C van Krimpen,S Rodenhuis,MJ van de Vijver,SC Linn,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The lancet oncology

VOLUME: 8

Page Numbers: 1079-87

Journal Abbreviation: Lancet Oncol.

ISSN: 1474-5488

DAY: 26

MONTH: 11

YEAR: 2007

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100957246

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

AFFILIATION: Department of Pathology, Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Lancet Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study RASTER Related Publications

• A note on manner of approach in the Rorschach test as a measure of psychic energy.
• A rapid disability rating scale.
• Acetylcholine neuroprotection against glutamate-induced excitotoxicity in adult pig retinal ganglion cells is partially mediated through alpha4 nAChRs.
• Age differences in the severity and outcome of burns.
• An orthopedic and neurological follow-up study of vertebral fractures in shock therapy.
• Career orientations and the quality of working life among medical interns and residents.
• Chronic serpiginous ulcer of the cornea (Moreen's ulcer) etiologic and therapeutic considerations.
• Cultural and sex differences in dietary patterns of the urban elderly.
• Ddb2 is a haploinsufficient tumor suppressor and controls spontaneous germ cell apoptosis.
• Diagnosis questioned.
• Evaluation of continuing education for long-term care personnel: impact upon attitudes and knowledge.
• Factors associated with patient evaluation of health care.
• Functioning of the elderly patient in relation to the physician's diagnosis of chronic brain syndrome.
• Genetic modification of cells for transplantation.
• Improving the nutritive value of flour; the use of enriched and non-enriched flour in diets similar to those consumed by certain low-income groups in South Carolina.
• Male nursing home patients: relocation and mortality.
• Objective and self-assessed health in the old and very old.
• Photostimulable phosphor digital radiography of the extremities: diagnostic accuracy compared with conventional radiography.
• Psychosocial needs of patients with acute respiratory failure.
• Social dysfunction among psychiatric and non-psychiatric outpatients.
• Sublingual application of a solution of oxalic and malonic acids to decrease clotting time in oral surgery.
• The Passerini reaction; optically active anilides.
• The infusion of fluids into the subarachnoid space of human beings.
• The rapid disability rating scale-2.
• Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
• What wives say about nursing homes.
• Who goes to nursing homes?
• [High frequency vacuum casting and multiple use of metals]
• [Modern preheating and pouring procedures. Technically realizable, economically feasible]
• [Not Available.]